Innovative biotech Wobble Genomics has appointed a Commercial Advisor to lead the design of its U.S. market entry strategy. As the company prepares to introduce its next-generation RNA and DNA analysis technology to a major global market, this advisory role will be key to identifying the right partnerships, customer segments, and go-to-market pathways.
The appointment enables Wobble Genomics to enter the U.S. with clarity and commercial focus, ensuring that its disruptive genomic sample-prep technology reaches high-value customers and accelerates adoption across research, diagnostics, and biopharma.
